Appia Bio
Margo Roberts, PhD, is former CSO of Kite Pharma (acquired by Gilead in 2017) and Lyell Immunopharma. At Kite, she built a talented research organization that played an instrumental role in the successful development of Yescarta®, and the clinical advancement of additional CAR/TCR-engineered T-cell therapies. Dr. Roberts has almost three decades of biomedical research experience in both biotechnology and academia and is the inventor on thirteen issued US patents and three published US patent applications related to CAR technology and tumor vaccine therapies. She completed her PhD and undergraduate studies at the University of Leeds in England.
This person is not in the org chart
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).